Table 3.
Key anti-CD19 CAR T-cell therapy trials in relapsed/refractory B acute lymphoblastic leukemia.
| ELIANA | MSKCC | ZUMA-3 | |
|---|---|---|---|
| CAR T-cell agent | Tisagenleucel | JCAR015 | Brexucabtagene autoleucel |
| Author (Years) | Maude (2018) | Park (2018) | Shah (2019) |
| Study phase | II | I | I/II |
| Study population | Pediatric/young adults | Adults | Adults |
| No. Patients | 75 | 53 | 45 |
| CR % | MRD negative: 81 | Overall: 83 | Overall: 68 RP2D: 84 |
| Median OS, mos | 19.1 | 12.9 | -- |
| Median EFS, mos | NR | 6.1 | -- |
| Median DoR, mos | NR | -- | RP2D: 12.9 |
| Median follow-up, mos | 13.1 | 29 | 16 |
DoR, duration of response; EFS, event-free survival; MRD, measurable residual disease; NR, not reached; RP2D, recommended phase II dose; mos, months.